Key Highlights
- MapLight Therapeutics shares are up 5.87% in pre-market trading to $12.26, extending Thursday's 1.76% close gain to $11.58.
- The company reported positive topline results from the Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, meeting its primary endpoint with a statistically significant reduction in PANSS total score.
- ZEPHYR also showed a positive cognitive-function signal and a favorable tolerability profile, supporting advancement into a registrational Phase 3 ZEPHYR-2 trial with topline results expected in 2028.
- The company ended the quarter with $351.3 million in cash, which, combined with a recent $150 million private placement, is expected to fund operations through 2028.
What's Driving the Gain
MapLight Therapeutics (NASDAQ:MPLT) shares are climbing in pre-market trading after the clinical-stage biopharmaceutical company reported positive Phase 2 results and provided a Business update alongside its second-quarter earnings. MapLight is a Redwood City, California-based company focused on developing circuit-specific therapies for central nervous system disorders including schizophrenia, Alzheimer's disease psychosis, autism spectrum disorder, and Parkinson's disease.
The primary catalyst is the Phase 2 ZEPHYR trial of ML-007C-MA, an M1/M4 muscarinic agonist being developed for adults with schizophrenia experiencing an acute exacerbation of psychosis. The trial met its primary endpoint, with the 210/3 mg twice-daily dose showing a statistically significant and clinically meaningful reduction in PANSS total score compared with placebo at Week 5. The drug also demonstrated improvement on a cognitive-function endpoint and separated from placebo on key secondary measures, while showing no serious or drug-related severe adverse events. The company plans to meet with the FDA to discuss a registrational path forward, including a Phase 3 ZEPHYR-2 trial.
Pipeline and Financial Position
Beyond schizophrenia, MapLight continues enrolling its Phase 2 VISTA trial evaluating ML-007C-MA in Alzheimer's disease psychosis, with topline results expected in the second half of 2027. The company also reported Phase 2 IRIS results for ML-004 in autism spectrum disorder; while the trial missed its primary endpoint on social communication, a prespecified subgroup of adolescents with moderate or greater baseline irritability showed clinically meaningful improvement. MapLight said it is now focusing resources primarily on ML-007C-MA and pausing Investment in earlier-stage preclinical programs.
On the financial side, Research and Development expenses rose to $53.4 million for the quarter from $26.8 million a year earlier, driving a net loss of $60.2 million compared with $29.8 million in the prior-year period. The company ended the quarter with $351.3 million in cash, cash equivalents, and investments. Combined with a recently announced $150 million private placement, MapLight expects its cash position to fund operations through 2028, covering both the VISTA and ZEPHYR-2 readouts.
Conclusion
MapLight Therapeutics shares are higher in pre-market trading as investors respond to positive late-stage clinical progress in its lead schizophrenia program, even as the company posts a wider quarterly loss. With a strengthened cash runway extending through 2028, the market appears to be weighing the clinical momentum in ML-007C-MA more heavily than near-term spending increases.



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...